|
The Food and Drug Administration has approved a new infusion-version of golimumab on July 18, in combination with methotrexate, for the treatment of adults with moderately to severely active rheumatoid arthritis.
Once-monthly subcutaneous injection of golimumab has been approved by FDA in 2009 as a treatment for moderately to severely active RA, active psoriatic arthritis, and active ankylosing spondylitis. Dosing regimen of intravenous infusion is 2 mg/kg given at weeks 0 and 4, then every 8 weeks over a 30-minute period. |
